Ventricular tachycardia (VT) is a crucial cause of sudden cardiac death (SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to lifethreatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in certain populations, with various underlying heart conditions, specific family history, and genetic variants. The targets of VT management are symptom alleviation, improved quality of life, reduced implantable cardioverter defibrillator shocks, prevention of reduction of left ventricular function, reduced risk of SCD, and improved overall survival. Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of guideline-endorsed VT treatment strategies in patients with structural cardiac abnormalities. Novel strategies such as epicardial ablation, surgical cryoablation, transcoronary alcohol ablation, pre-procedural imaging, and stereotactic ablative radiotherapy are an appealing area of res- Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version. Core tip: Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of ventricular tachycardia (VT) treatment management, but both treatments have limited efficacy and important adverse effects. Catheter ablation for cardiomyopathic (scarrelated) VT is associated with recurrence rates as high as 50% at 6 mo. Implantable cardioverter defibrillator provides a safety net; however, there is an increased need for more effective and safer methods to decrease VT recurrence episodes. We sought to review current literature in order to summarize data on innovative techniques for VT treatment.
INTRODUCTION
Sudden cardiac death (SCD) is a vital public health is sue, accountable for almost 50% of all cardiovascular deaths [1] . In the last three decades, SCD was the le ading cause for almost 230000 to 350000 deaths per annum in the United States [1] . Ventricular arrhythmias account for 25% to 36% of witnessed sudden cardiac arrests (SCA) at home and 38% to 79% of witnessed SCA in public [2] . Ischemic heart disease, structural disorders, vario us forms of cardiomyopathy associated with myocardial fibrosis, cardiac channelopathies, myocarditis, congen ital heart diseases, and other genetic rare disorders are associated with ventricular arrhythmias [1] . Even though treatment for heart failure lowers mo rtality and SCD, it was unsuccessful in lessening ve ntricular tachycardia (VT) recurrences [3] . Implantable cardioverter defibrillators (ICD) are very effective in eliminating VT episodes and in lowering the possibility of SCD, but they are not useful for arrhythmia preventi on [4] . When the VT substrate manifests, antiarrhythm ic drug treatment or catheter ablation are the current choices to reduce VT episodes [5] . Catheter ablation and antiarrhythmic drug therapy though, are also limited by incomplete efficacy, unfavorable side effects, and procedural risk [5] . In this review, we outline the current advances in VT treatment options and describe the im aging modalities, progress, and novel strategies.
LITERATURE SEARCH
We have collected all experimental and clinical inve stigations focused on new aspects that could be esse ntial for tailoring VT therapy according to underlying et iology, in order to achieve higher efficacy. The MEDLINE database was screened for studies with the medical term "ventricular tachycardia" and keywords "treatment", or "ablation", or "management". We restricted our search to English literature.
NOVEL VT THERAPIES

Epicardial catheter ablation
Endocardial catheter ablation and antiarrhythmic drug treatment are currently the mainstays of VT treatm ent [1, 3] . However, the procedural success rates of VT are quite variable due to the heterogeneous substrates that reflect the variety of pathophysiological processes [6, 7] . The success rate of endocardial ablation in patients wi th outflow tract VT is 84%, in patients with papillary muscle VT is 60%, and in patients with idiopathic left ventricular VT is 70% [6] . Moreover, the VT recurrence rat es of endocardial ablation in ischemic cardiomyopathy patients are between 23% and 49% and in dilated car diomyopathy patients between 46% and 61% [7] . Non ischemic cardiomyopathy patients have worse outcom es than ischemic cardiomyopathy patients due to scar patterns with epicardial and intramural sites [7] . Epicardial ablation has emerged as a potential alt ernative ablation strategy in order to increase the su ccess rate in complex substrates and to eliminate VT in patients with different cardiomyopathies and more recently in patients with Brugada syndrome [811] . Percu taneous approach to the pericardial area facilitates ep icardial ablation when the VT substrate is situated in the subepicardium [8] (Figure 1 ). Adjacency to coronary circulation and the phrenic nerve may hinder the proce dure in certain situations [9] . In patients with previous heart surgery or previous epicardial ablation attempts, percutaneous access may not be possible and as such, videoassisted thoracoscopy may be a good and minima lly invasive alternative to open surgery [12] . Epicardial ablation is a safe procedure with low co mplication rates [13] . Pericardial effusion is the most co mmon complication [13] . Damage to subdiaphragmatic or gans and hemorrhage from diaphragmatic vessels have also been reported [13] . Della Bella et al [14] evaluated the possible benefit of endoepicardial catheter ablation for the management of VT in 528 patients with any form of structural cardiac disorder (Figure 2 ). Endoepicardial catheter ablation re sulted in a VT recurrence rate of 34.1%, in comparison to a rate of up to 50% with the standard endocardial approach [14] .
Intramyocardial infusion-needle catheter ablation
Transcoronary alcohol ablation has emerged to approach deep intramyocardial substrate in patients not amena ble to endoepicardial catheter ablation (mechanical valve, thrombus, significant comorbidities) [15, 16] . Trans coronary alcohol ablation requires the injected dose of sterile pure ethanol with proximal balloon expansion to a culprit vessel with a target of abolishing perfusion [15, 16] ( Figure 3 ). This method can prevent recurrent VT, VT storm and can control incessant VT [15, 16] . The exact rec ognition of the target vessel and the existence of coll aterals may hinder the adoption of the method [1517] . Kim et al [15] introduced the novel use of cardioplegia as a mapping technique in order to identify the critical VT isthmus to facilitate effective transcoronary ethanol ablation and avoid irreversible myocardial injury. Furt hermore, Sapp et al [17] showed that intramyocardial needle mapping and ablation with saline infusion could create deep injuries and is a practical and efficient method. Intracoronary wire mapping and coil embo lization have also been utilized just as alcohol ablation to target VT arising from intraventricular septum [18] . After intracoronary wire mapping and recognition of a culprit vessel, coils are directed to embolize the branch, eliminating the desired target perfusion [18] .
Bipolar ablation
Bipolar ablation between two ablation catheters locat ed on either position of the septum from both ventricles improves lesion transmurality because it depends less on catheter contact and alignment [19, 20] (Figure 4 ). Bi polar ablation has the theoretical benefit of producing more powerful energy and providing deeper lesions, in comparison to two separate unipolar catheters [19, 20] . Sakamoto et al [20] recently successfully eliminated the critical VT circuit in a patient with an arrhythmogenic substrate (cardiac sarcoidosis), utilizing bipolar ablation.
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Cardiac sympathetic denervation
Accumulated evidence strongly suggests a role of sy mpathetic neuromodulation in controlling refractory VT [1924] . Cardiac sympathetic denervation surgery has been proven to be useful for the management of con genital long QT syndrome and catecholaminergic pol ymorphic VT [21] . The procedure requires extraction of the lower fraction of the stellate ganglion and T2T4 sympathetic thoracic ganglia [21] . Complications regard ing the procedure were infrequent, with 4% developing acute ptosis or Horner syndrome [21] . Vaseghi et al [21] sh owed that cardiac sympathetic denervation has greater shock free survival as well as a considerable decline in shock burden in patients with recurrent VT or VT storm, regardless of antiarrhythmic drug therapy and cathe ter ablation. In addition, bilateral cardiac sympathetic denervation appeared to be more efficacious than left sided denervation [21, 22] . Augmented sympathetic activity leads to early and delayed afterdepolarization, enhances diffuse repolar ization, leading to ventricular electrical susceptibility and increases the possibility of malignant VT [23] . Stellate ganglionectomy lengthens the ventricular refractory period and raises the VF threshold, decreasing VT or VF inducibility in the context of myocardial infarction [23, 24] . Locally invasive sympathetic ganglion block could select individuals with greater possibilities of longterm clinical benefits prior to sympathetic denervation [23, 24] .
Renal sympathetic denervation
Enhanced sympathetic tone shortens the ventricular effective refractory period, enhances automaticity, and lowers the threshold for ventricular arrhythmias [2527] . Feyz et al [25] performed bilateral renal denervation in a patient with polymorphic VT with excellent results. Aksu et al [27] also showed that catheterbased renal denervation was successful in a patient with an electri cal storm due to catecholaminergic polymorphic VT. Ho wever, the microanatomy of human renal vessels has great variability. Accessory renal vessels that bifurcated early can also influence the result negatively, and the re is still the absence of procedural endpoint during the technique [26] . As a result, renal sympathetic denervation is not cu rrently recognized as an ideal or approved VT treatment method [2527] . However, certain ventricular arrhythmias do not terminate after catheter ablation, thus making renal sympathetic denervation a possible option for patients in whom other ablative approaches were ineffective [25, 27] .
Stereotactic radioablative therapies
Despite catheteroriented ablation, which applies rad iofrequency or freezing to damage tissues, radiotherapy is based on photons from Xrays or gamma rays to in jure the desired target, mainly cancer. Through novel distribution methods such as intensitymodulated rad iotherapy, a dosage of radiotherapy can be precisely and accurately directed to the desired site, while diminishing [28, 29] . In comparison to radiofrequency or cry oenergy, the damage from ablative radiotherapy pro gresses over days to months, needing time for the total tissue damage to be shown [28, 29] . The first patient was treated on a robotic radiosur gery system (CyberKnife ® , Accuray, Sunnyvale, CA, United States) in 2012 [28] . The followup revealed no de finite acute or late adverse effects, and a sevenmonth reduction burden in VT on standard antiarrhythmic drug therapy, suggesting a potential transient benefit of this method [28] . Cuculich et al [29] investigated five patients with in creasedrisk, refractory VT. The authors focused on arr hythmogenic scar sites by merging anatomical imaging with noninvasive electrocardiographic imaging during VT that was produced using an ICD [29] . Patients were tr eated with a single dose of 25 Gy while awake, using a noninvasive distribution of accurate ablative radiation with stereotactic body radiation treatment [29] . Cuculich et al [29] reported a reduction in events of VT in all five patients.
Cryoablation
Catheter radiofrequency ablation of VT originating from the left ventricle's papillary muscles has been linked to conflicting outcomes [30, 31] . Rivera et al [31] investigated twentyone patients with drugrefractory VT, who und erwent catheter cryoablation or radiofrequency ablation. Cryoablation was correlated with greater success rat es and smaller recurrence rates than radiofrequency procedures, superior catheter support, and smaller fr equency of polymorphic arrhythmias [31] . Marai et al [30] recently used cryoablation guided by intracardiac ech ocardiography, 3dimensional mapping system, and image integration to treat a patient with refractory VT originating from papillary muscle with excellent results.
Surgical therapy for VT
Catheter ablation provides efficient outcomes for su dosage to adjoining healthy tissues [28, 29] . Ablative radiotherapy is generally a noninvasive, ou tpatient method, which does not involve anesthesia [28, 29] . Potential risks consist of damage to tissue next to the ablated site, such as brain edema for intracranial les to SCD [39, 40] . CPVT is associated with mutations in the gene encoding the cardiac RyR2, a cardiac ryanodine rec eptor protein which is involved in calcium homeostasis and mutations in the gene that encodes calsequestrin (CASQ2), a protein that interacts with RyR2 [3941] . Denegri et al [42] showed that viral gene transfer of wildtype CASQ2 into the heart of mice prevented and reverted severe manifestations of CPVT. Furthermore, Lodola et al [43] infected induced pluripotent stem cel ls with an adenoassociated viral vector serotype 9 (AAV9) encoding the human CASQ2 gene and noticed a significant decline in the percentage of delayed aft erdepolarizations. Li et al [44] used tetracaine, a local anesthetic drug with known RyR2 inhibiting action, in mice and showed that the drug efficiently halted the induction of VT in a mouse model of CPVT.
INNOVATIVE MODALITIES FOR VT AND FUTURE CLINICAL APPLICATIONS
Endoepicardial ablation reduces VT recurrences, but not all patients have a VT substrate [45] . Contrastenhanced magnetic resonance imaging (ceMRI) is utilized to identify VT substrate after myocardial infarction [45] . Ar ena et al [45] showed that ceMRIbased endoepicardial signal intensity mapping in a porcine model allowed ch aracterization of the epicardial VT substrate. Klein et al [46] used 3D metaiodobenzylguanidine (MIBG) imaging to guide VT ablation. MIBG innervation defects are greater than scars produced from bipolar voltage maps, and the investigation showed that 36% of successful ablative locations were situated in sectio ns of irregular innervation and normal voltage, suggesti ng that innervation maps may identify additional VT ablation sites [46] . Zhang et al [47] investigated noninvasive highresol ution mapping and electrocardiographic imaging to pro vide epicardial substrate information. Electrocardiogra phic imaging identified scar electrophysiologic substrates in ischemic cardiomyopathy patients [47] . Cardiac ripple mapping for slow conducting channels is an innovative technique to integrate voltage and ac tivation mapping [48, 49] . Cardiac ripple mapping allows the concurrent vision of voltage and activation data and facilitates recognition of slow conduction channels with in scar areas in the myocardium that could be probable VT ablation sites [48, 49] . Table 1 summarizes the studies investigating novel approaches for the treatment of VT.
CONCLUSION
The management of patients with VT can be dema nding. ICD implant led to a considerable difference in the survival of subjects with VT, but the estimate of subjects with recurrent ICD shocks is still a growing issue. Antiarrhythmic drug treatment has reduced effectiveness and is correlated with serious adverse effects. Catheter ablation remains the cornerstone in stained monomorphic VT, but certain situations, such as the existence of mural thrombus and heavy calcifica tion, can lead to adverse results [32, 33] . Higuchi et al [33] suc cessfully treated a 67yearold patient with sustained monomorphic VT due to ventricular scar and resistant to endocardial radiofrequency ablation, by left ventricular reconstruction with cryoablation. Li et al [34] conducted a retrospective investigation of 38 consecutive surgical epicardial VT ablation procedures and compared the results with those of a propensitymatched percutane ous epicardial access control group. Surgical epicardial access after heart surgery for VT ablation showed no statistical difference in longterm results in comparison to the percutaneous epicardial group [34] . Recently, Berte et al [35] presented the first animal survey utilizing a more potent cryoablation system that can generate larger, transmural ventricular lesions fr om both the endocardium and the epicardium. Surgical cryoablation in sheep had no acute macroscopic vasc ular or extracardiac damage and resulted in 100% suc cessful lesions at necropsy [35] . In some patients with nonischemic cardiomyopa thy and VT refractory to standard therapy or undergoing cardiac surgery, surgical ablation may be an alternati ve option for potentially reducing the burden of ICD shocks during longterm followup [36] . Liang et al [36] showed that detailed arrhythmogenic substrate in the electrophysiology lab before surgery, in conjunction with a direct scar and radiofrequency ablation lesions visualization in the operating room, is crucial for guiding surgical ablation.
Extracorporeal life support for refractory VT
Extracorporeal life support is a highly efficient bridging treatment in patients with refractory VT associated with cardiogenic shock [37] . Extracorporeal life support allows the usage of negative inotropic antiarrhythmic drug therapy, leads to the weaning of catecholamine delivery, thus resolving the dangerous period of the ca techolamine driven electrical storm [37] . The utilization of extracorporeal life support maintains hemodynamic support during an ablation procedure, while mapping and induction of VT are commenced and provides suf ficient vital organ perfusion in patients with refractory VT [37] . Current literature suggests the usage of extra corporeal life support, as it has proven to be a safe, pr actical and efficient therapeutic solution when traditional treatments have failed [37] .
Steroid pulse therapy
Okabe et al [38] successfully treated a patient with cardi ac sarcoidosis associated with VT using steroid pulse therapy.
Gene therapy
Catecholaminergic polymorphic VT (CPVT) is a rare ca rdiac ion channelopathy induced by anomalies in proteins that regulate Ca 2+ transport in heart cells that can lead [14] Clinical 528 Endo-epicardial Ablation Pericardial effusion, tamponade
Kim et al [15] Clinical 1 Cardioplegia/Transcoronary alcohol ablation Atrioventricular block, extensive myocardial damage, perforation Sapp et al [17] Clinical 8 Intramyocardial infusion-needle catheter ablation Atrioventricular block, perforation, tamponade Tholakanahalli et al [18] Clinical 2 Intracoronary wire mapping and coil embolization Atrioventricular block, coronary injury, embolization of unintended branches Vaseghi et al [21] Clinical 121 Cardiac sympathetic denervation Hemothorax, pneumothorax, ptosis or Horner syndrome Cuculich et al [29] Clinical 5 Stereotactic radioablation therapy Fatigue Rivera et al [31] Clinical 21 Cryoablation -Li et al [34] Clinical 38 Surgical epicardial ablation Ventricle laceration Berte et al [35] Experimental 5 (sheep) Surgical cryoablation -Liang et al [36] Clinical 20 Surgical cryoablation -Denegri et al [42] Experimental 25 (mice) Viral gene transfer of wild-type CASQ2 -Li et al [44] Experimental 9 (mice) Tetracaine derivatives (RyR2 inhibitors) -Arenal et al [45] Experimental 31 (pigs) MRI-based signal intensity mapping for epicardial substrate
Coronary occlusion
Klein et al [46] Clinical 15 3D meta-iodobenzyl-guanidine innervation maps to assess substrate and successful ablation sites -Zhang et al [47] Clinical 32 Non-invasive high-resolution endocardial and epicardial mapping and electro-cardiographic imaging -Luther et al [48] Clinical 15 Cardiac ripple mapping for slow conducting channels -Jamil-Copley et al [49] Clinical 21 Cardiac ripple mapping for slow conducting channels -
